Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imcera

This article was originally published in The Gray Sheet

Executive Summary

Board recommendation for corporate name change to Mallinckrodt Group, Inc. will be considered at a March 15 special shareholders meeting in St. Louis. President and CEO Ray Holman says the Imcera name "no longer reflects our current business or our future vision and direction." Currently, he points out, "70% of [the company's] business is already conducted under the Mallinckrodt name" through the medical products and specialty chemicals operations. The animal health products unit, Pitman-Moore, would change its name to Mallinckrodt Veterinary under the board's proposal. The company, formerly International Mining and Chemicals Corp. (IMC), took the name Imcera in 1990, four years after it purchased Mallinckrodt and the year after it bought Coopers Animal Health. Corporate headquarters, currently located in Northbrook, Illinois, will be relocating to St. Louis in mid-March
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel